Global Brain has invested in EditForce, Inc. (EditForce), a company developing unique DNA / RNA editing technology to bring innovation to various industries, through its GB-VII Growth Fund Investment Limited Partnership (GB-VII) and its KDDI Open Innovation Fund III (KOIF III).

EditForce has developed DNA/RNA editing tools by integrating pentatricopeptide repeat (PPR) proteins with various enzymes. As opposed to other genome editing technology, this technology enables the editing of not only DNA sequences but also RNA sequences. Currently, EditForce has focused on the field of pharmaceuticals and has grown through business alliances with multiple pharmaceutical companies.

Global Brain has decided to invest in EditForce, thinking highly of their unique DNA / RNA editing technology and strong management team. Global Brain will continue leveraging its resources to assist EditForce in fast-growing on the field of pharmaceuticals and expanding their business into new field such as agriculture and chemical.

About EditForce, Inc.

Location
4F Fukuoka Tenjin Fukoku Seimei Bldg. 1-9-17, Tenjin, Chuo-ku, Fukuoka
Representative
Takashi Ono
Founded
May 15, 2015
URL
https://www.editforce.co.jp/

About GB-VII

Name
GB-VII Growth Fund Investment Limited Partnership
General Partner
Global Brain Corporation

About KOIF III

Name
KDDI Open Innovation Fund III
General Partner
Global Brain Corporation
Fund Size
20 Billion JPY

About Global Brain

Location
Tokyo, Japan
Representative
Yasuhiko Yurimoto
Founded
January, 1998
URL
https://globalbrains.com/